Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug‐Induced Liver Injury

Tolcapone and entacapone are catechol‐O‐methyltransferase (COMT) inhibitors developed as adjunct therapies for treating Parkinson's disease. While both drugs have been shown to cause mitochondrial dysfunction and inhibition of the bile salt export protein (BSEP), liver injury has only been asso...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :CPT Pharmacometrics Syst Pharmacol
Главные авторы: Longo, DM, Yang, Y, Watkins, PB, Howell, BA, Siler, SQ
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2016
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4728295/
https://ncbi.nlm.nih.gov/pubmed/26844013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12053
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы